206 related articles for article (PubMed ID: 28026920)
1. Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
Halseth A; Shan K; Walsh B; Gilder K; Fujioka K
Obesity (Silver Spring); 2017 Feb; 25(2):338-345. PubMed ID: 28026920
[TBL] [Abstract][Full Text] [Related]
2. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
[TBL] [Abstract][Full Text] [Related]
3. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
[TBL] [Abstract][Full Text] [Related]
4. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Hollander P; Gupta AK; Plodkowski R; Greenway F; Bays H; Burns C; Klassen P; Fujioka K;
Diabetes Care; 2013 Dec; 36(12):4022-9. PubMed ID: 24144653
[TBL] [Abstract][Full Text] [Related]
5. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
Jain AK; Kaplan RA; Gadde KM; Wadden TA; Allison DB; Brewer ER; Leadbetter RA; Richard N; Haight B; Jamerson BD; Buaron KS; Metz A
Obes Res; 2002 Oct; 10(10):1049-56. PubMed ID: 12376586
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
Hong K; Herrmann K; Dybala C; Halseth AE; Lam H; Foreyt JP
Clin Obes; 2016 Oct; 6(5):305-12. PubMed ID: 27477337
[TBL] [Abstract][Full Text] [Related]
7. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
[TBL] [Abstract][Full Text] [Related]
8. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
Padwal R
Curr Opin Investig Drugs; 2009 Oct; 10(10):1117-25. PubMed ID: 19777400
[TBL] [Abstract][Full Text] [Related]
9. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
Grilo CM; Lydecker JA; Morgan PT; Gueorguieva R
Clin Ther; 2021 Jan; 43(1):112-122.e1. PubMed ID: 33218742
[TBL] [Abstract][Full Text] [Related]
10. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.
Anderson JW; Greenway FL; Fujioka K; Gadde KM; McKenney J; O'Neil PM
Obes Res; 2002 Jul; 10(7):633-41. PubMed ID: 12105285
[TBL] [Abstract][Full Text] [Related]
11. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.
Wilcox CS; Oskooilar N; Erickson JS; Billes SK; Katz BB; Tollefson G; Dunayevich E
Addict Behav; 2010 Mar; 35(3):229-34. PubMed ID: 19926400
[TBL] [Abstract][Full Text] [Related]
12. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy.
Fujioka K; Plodkowski R; O'Neil PM; Gilder K; Walsh B; Greenway FL
Int J Obes (Lond); 2016 Sep; 40(9):1369-75. PubMed ID: 27328752
[TBL] [Abstract][Full Text] [Related]
13. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Wadden TA; Foreyt JP; Foster GD; Hill JO; Klein S; O'Neil PM; Perri MG; Pi-Sunyer FX; Rock CL; Erickson JS; Maier HN; Kim DD; Dunayevich E
Obesity (Silver Spring); 2011 Jan; 19(1):110-20. PubMed ID: 20559296
[TBL] [Abstract][Full Text] [Related]
14. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study.
Dannon PN; Lowengrub K; Musin E; Gonopolski Y; Kotler M
J Clin Psychopharmacol; 2005 Dec; 25(6):593-6. PubMed ID: 16282845
[TBL] [Abstract][Full Text] [Related]
15. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain.
Toll BA; Leary V; Wu R; Salovey P; Meandzija B; O'Malley SS
Addict Behav; 2008 Jan; 33(1):173-9. PubMed ID: 17587504
[TBL] [Abstract][Full Text] [Related]
16. Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample.
Dalton M; Finlayson G; Walsh B; Halseth AE; Duarte C; Blundell JE
Int J Obes (Lond); 2017 Aug; 41(8):1232-1236. PubMed ID: 28373674
[TBL] [Abstract][Full Text] [Related]
17. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.
Billes SK; Sinnayah P; Cowley MA
Pharmacol Res; 2014 Jun; 84():1-11. PubMed ID: 24754973
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with naltrexone and bupropion for obesity.
Billes SK; Greenway FL
Expert Opin Pharmacother; 2011 Aug; 12(11):1813-26. PubMed ID: 21689063
[TBL] [Abstract][Full Text] [Related]
19. Naltrexone for the treatment of obesity: review and update.
Lee MW; Fujioka K
Expert Opin Pharmacother; 2009 Aug; 10(11):1841-5. PubMed ID: 19537999
[TBL] [Abstract][Full Text] [Related]
20. Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
Guerdjikova AI; Walsh B; Shan K; Halseth AE; Dunayevich E; McElroy SL
Adv Ther; 2017 Oct; 34(10):2307-2315. PubMed ID: 28918581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
